Endo International Plc (ENDP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Published : Dec-2017

No. of Pages : 163

order by fax Inquire before Buying request discount

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 9
Endo International Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 10
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 11
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 12
Endo International Plc, Medical Devices Deals, 2011 to YTD 2017 14
Endo International Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 15
Endo International Plc, Pharmaceuticals & Healthcare, Deal Details 20
Asset Purchase 20
Endo International Acquires Portfolio of Branded and Generic Products 20
Endo International Completes Acquisition of Sumavel DosePro Migraine Therapy Business from Zogenix 21
Par Pharma to Acquire Certain Assets of Nuray Chemicals for USD20 Million 22
Paladin Labs To Acquire Antibiotic Binotal In Latin America From Bayer 23
Par Pharma Completes Acquisition Of Generic Products From Watson Pharma And Actavis 24
Endo Pharma Acquires US Patents For Oxymorphone From Johnson Matthey 26
Par Pharma Acquires Rights And Assets To Three Products From Teva Pharma 27
Paladin Labs Completes Acquisition Of Tempra From Bristol-Myers Squibb 29
Private Equity 30
Endo International Sells Grupo Farmaceutico Somar to Advent International 30
Altaris Capital Partners Completes Acquisition Of HealthTronics From Endo Health Solutions For US$130 Million 31
TPG Capital Completes Acquisition Of Par Pharma, Generic Drug Company, For US$1.9 Billion 32
Partnerships 34
IntelGenx Enters into Co-Development Agreement with Endo Ventures 34
ARIAD Pharma Enters into Distribution Agreement with Paladin 35
Vyrix Pharma Enters Into Distribution Agreement With Paladin Labs For Zertane 36
IntelGenx Enters Into Development And Commercialization Agreement With Par Pharma For Two New Products 37
Auxilium Pharma And Swedish Orphan Biovitrum Enter Into Co-Development Agreement For Xiapex 38
Moberg Extends Distribution Agreement With Paladin Labs For Kerasal Nail 39
GVK Biosciences Enters Into Research Agreement With Endo Pharma 40
Paladin Labs Enters Into Distribution Agreement With Allergy Therapeutics For Pollinex-R 41
Paladin Labs Enters Into Distribution Agreement With Moberg Derma For Emtrix 42
Par Pharma Enters Into Distribution Agreement With AstraZeneca For Atacand HCT 43
Auxilium Pharma Enters Into Co-Promotion Agreement With GlaxoSmithKline For Testim 1% 44
Mersana Therapeutics Enters Into Co-Development Agreement With Endo Pharma 45
IntelGenx Enters Into Development And Commercialization Agreement With Par Pharma 46
Paladin Labs Enters Into Distribution Agreement With Common Sense 47
Intellipharmaceutics Expands Co-Development Agreement With Par Pharma For Focalin XR 48
Syngene International Expands Co-Development Agreement With Endo Pharma 49
Endo Pharma Enters Into Research Collaboration With Orion 50
Licensing Agreements 51
Paladin Labs Enters into Licensing Agreement with Veloxis Pharma 51
Endo International Amends Licensing Agreement with BioSpecifics Technologies 52
Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 53
Auxilium Exercises Option For Licensing Agreement With Biospecifics To Include Potential Treatment of Cellulite As Additional Indication 54
Sucampo Pharma and R-Tech Ueno Enter into Licensing Agreement with Par Pharma 56
Paladin Labs Enters Into Licensing Agreement With Bioniche Life Sciences 57
Paladin Labs Enters Into Licensing Agreement With Apeiron Biologics For APN311 59
Endo Pharma Amends Licensing Agreement with Grunenthal 60
Par Pharma Enters Into Licensing Agreement With Handa Pharma For Seroquel XR 61
Paladin Labs Enters Into Licensing Agreement With Dynamiclear For Dynamiclear Rapid 62
QrxPharma Enters Into Licensing Agreement With Paladin Labs For Moxduo 63
Nuvo Research Enters Into Licensing Agreement With Paladin Labs For Synera 65
Par Pharma Enters Into Licensing Agreement With Handa Pharma For ANDA 66
Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 67
Paladin Labs Enters into Licensing Agreement With Immuron For Travelan 69
Somaxon Pharma Enters Into Licensing Agreement With Paladin Labs For Silenor 70
Paladin Labs Enters Into Licensing Agreement With Elan For Hydrocodone 71
Paladin Labs Enters Into Licensing And Distribution Agreement With Takeda For Fomepizole 72
MediGene Enters Into Licensing Agreement With Triton Pharma For Veregen 73
Auxilium Pharma Enters Into Licensing Agreement With Asahi Kasei For XIAFLEX 74
Equity Offering 76
Endo International Raises USD2.3 Billion in Public Offering of Shares 76
Paladin Labs Completes Private Placement For US$40 Million 78
Debt Offering 80
Endo International Prices Private Placement of 5.875% Notes Due 2024 for USD300 Million 80
Endo Prices Private Placement of Notes Due 2023 for USD1.6 Billion 81
Endo International Prices Private Placement of 6% Notes Due 2023 for USD1.64 Billion 82
Endo International Prices Private Placement of 6% Notes Due 2025 for USD1.2 Billion 83
Endo International Completes Private Placement of 5.375% Notes Due 2023 for USD750 Million 84
Endo Health Solutions Completes Private Placement Of Notes Due 2022 For US$700 Million 85
Auxilium Pharma Completes Public Offering Of Notes Due 2018 For US$350 Million 86
Par Pharma Completes Private Placement Of Notes Due 2020 For US$490 Million 87
Endo Pharma Completes Private Placement Of Senior Unsecured Notes Due 2019 For US$500 Million 88
Endo Pharma Completes Private Placement Of Senior Unsecured Notes Due 2022 For US$400 Million 89
Asset Transactions 90
Rising Pharma to Acquire Three ANDAs from Endo International 90
Braeburn Pharma Acquires Risperidone Implant from Endo Pharma 91
Nuvo Research Reacquires Pennsaid Rights from Paladin Labs 92
Rising Pharma Acquires Doxercalciferol, Paricalcitol and Dutasteride from Par Pharma 93
Trendlines Acquires Intellectual Property from Endo 94
AsanaBioSciences Completes Acquisition of Drug Discovery Platform from Endo Pharma 95
Acquisition 96
Acino Pharma Acquires Litha Healthcare from Endo International 96
Endo International Acquires Par Pharma from TPG Capital for USD8.05 Billion 98
Par Pharma Acquires Innoteq for USD27 Million 100
Endo International Acquires Auxilium Pharma for USD2.6 Billion 101
Par Pharma Reportedly Acquires Ethics Bio Lab 103
Endo International Completes Acquisition of Dava Pharma for USD600 Million 104
Endo International Completes Acquisition of Grupo Farmaceutico Somar 105
Endo Health Solutions Completes Acquisition Of Paladin Labs For US$1.6 Billion 106
Par Pharma Acquires JHP Group for USD488 Million 109
Endo Health Solutions Completes Acquisition Of Boca Pharmacal For US$225 Million 110
Paladin Labs Acquires Triton Pharma 112
Paladin Labs Completes Acquisition Of Allon Therapeutics 113
Auxilium Pharma Acquires Actient From GTRC 114
Paladin Labs Completes Acquisition Of Majority Stake In Ativa Pharma 116
Paladin Labs Completes Acquisition Of Remaining 55.01% Stake In Pharmaplan, Generic Pharma Company 117
Litha Healthcare Group Completes Acquisition Of Pharmaplan From Paladin Labs For US$60.7 Million 118
Par Pharma Completes Acquisition Of Edict Pharma, Generic Pharma Company, For US$24.9 Million 120
Par Pharma Acquires Anchen Pharma For US$410 Million 121
Paladin Labs Completes Acquisition Of Labopharm 123
Endo Pharma Acquires American Medical Systems 125
Endo Pharma To Acquire A Pharma Company 127
Endo International Plc - Key Competitors 128
Endo International Plc - Key Employees 129
Endo International Plc - Locations And Subsidiaries 131
Head Office 131
Other Locations & Subsidiaries 131
Recent Developments 133
Strategy And Business Planning 133
Jul 21, 2017: Endo to Restructure Manufacturing Network 133
Financial Announcements 134
Nov 09, 2017: Endo Reports Third-Quarter 2017 Financial Results 134
Oct 30, 2017: Endo Announces Certain Preliminary Financial Results for Third-Quarter 2017 and Affirms Selected 2017 Financial Guidance 136
Aug 08, 2017: Endo Reports Second-Quarter 2017 Financial Results 137
May 09, 2017: Endo Reports First-Quarter 2017 Financial Results 139
Feb 28, 2017: Endo Reports Fourth-Quarter And Full-Year 2016 Financial Results 142
Nov 08, 2016: Endo Reports Third Quarter 2016 Financial Results 145
Aug 08, 2016: Endo Reports Second Quarter 2016 Financial Results 147
May 05, 2016: Endo Reports First Quarter 2016 Financial Results 149
Feb 29, 2016: Endo Reports Fourth Quarter And Full Year 2015 Financial Results 151
Corporate Communications 153
Nov 08, 2017: Endo Announces Appointment of Dr. Sharad S. Mansukani to Board of Directors and Resignation of Mr. Douglas S. Ingram 153
Dec 20, 2016: Endo Announces Appointment of Blaise Coleman as Chief Financial Officer 154
Nov 07, 2016: Endo Strengthens Leadership Team with Appointment of Two Key Executives 155
Oct 20, 2016: Endo Announces Departure of Chief Financial Officer 156
Sep 23, 2016: Endo Names Paul Campanelli President and Chief Executive Officer 157
Aug 08, 2016: Endo Announces Appointment of Joseph J. Ciaffoni as President, U.S. Branded Pharmaceuticals 158
May 05, 2016: Endo Announces Appointment of Douglas S. Ingram and Todd B. Sisitsky to its Board of Directors 159
May 05, 2016: Endo Announces Change to Senior Management Team 160
Legal and Regulatory 161
Jun 07, 2017: Endo Announces Entry of Significant Case Management Order in Mesh Multidistrict Litigation 161
Other Significant Developments 162
Jan 26, 2017: Endo Announces Actions to Drive Greater Efficiency and Business Alignment 162
Appendix 163
Methodology 163
About GlobalData 163
Contact Us 163
Disclaimer 163

List of Tables
Endo International Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 9
Endo International Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 10
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 11
Endo International Plc, Deals By Therapy Area, 2011 to YTD 2017 12
Endo International Plc, Medical Devices Deals, 2011 to YTD 2017 14
Endo International Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 15
Endo International Acquires Portfolio of Branded and Generic Products 20
Endo International Completes Acquisition of Sumavel DosePro Migraine Therapy Business from Zogenix 21
Par Pharma to Acquire Certain Assets of Nuray Chemicals for USD20 Million 22
Paladin Labs To Acquire Antibiotic Binotal In Latin America From Bayer 23
Par Pharma Completes Acquisition Of Generic Products From Watson Pharma And Actavis 24
Endo Pharma Acquires US Patents For Oxymorphone From Johnson Matthey 26
Par Pharma Acquires Rights And Assets To Three Products From Teva Pharma 27
Paladin Labs Completes Acquisition Of Tempra From Bristol-Myers Squibb 29
Endo International Sells Grupo Farmaceutico Somar to Advent International 30
Altaris Capital Partners Completes Acquisition Of HealthTronics From Endo Health Solutions For US$130 Million 31
TPG Capital Completes Acquisition Of Par Pharma, Generic Drug Company, For US$1.9 Billion 32
IntelGenx Enters into Co-Development Agreement with Endo Ventures 34
ARIAD Pharma Enters into Distribution Agreement with Paladin 35
Vyrix Pharma Enters Into Distribution Agreement With Paladin Labs For Zertane 36
IntelGenx Enters Into Development And Commercialization Agreement With Par Pharma For Two New Products 37
Auxilium Pharma And Swedish Orphan Biovitrum Enter Into Co-Development Agreement For Xiapex 38
Moberg Extends Distribution Agreement With Paladin Labs For Kerasal Nail 39
GVK Biosciences Enters Into Research Agreement With Endo Pharma 40
Paladin Labs Enters Into Distribution Agreement With Allergy Therapeutics For Pollinex-R 41
Paladin Labs Enters Into Distribution Agreement With Moberg Derma For Emtrix 42
Par Pharma Enters Into Distribution Agreement With AstraZeneca For Atacand HCT 43
Auxilium Pharma Enters Into Co-Promotion Agreement With GlaxoSmithKline For Testim 1% 44
Mersana Therapeutics Enters Into Co-Development Agreement With Endo Pharma 45
IntelGenx Enters Into Development And Commercialization Agreement With Par Pharma 46
Paladin Labs Enters Into Distribution Agreement With Common Sense 47
Intellipharmaceutics Expands Co-Development Agreement With Par Pharma For Focalin XR 48
Syngene International Expands Co-Development Agreement With Endo Pharma 49
Endo Pharma Enters Into Research Collaboration With Orion 50
Paladin Labs Enters into Licensing Agreement with Veloxis Pharma 51
Endo International Amends Licensing Agreement with BioSpecifics Technologies 52
Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 53
Auxilium Exercises Option For Licensing Agreement With Biospecifics To Include Potential Treatment of Cellulite As Additional Indication 54
Sucampo Pharma and R-Tech Ueno Enter into Licensing Agreement with Par Pharma 56
Paladin Labs Enters Into Licensing Agreement With Bioniche Life Sciences 57
Paladin Labs Enters Into Licensing Agreement With Apeiron Biologics For APN311 59
Endo Pharma Amends Licensing Agreement with Grunenthal 60
Par Pharma Enters Into Licensing Agreement With Handa Pharma For Seroquel XR 61
Paladin Labs Enters Into Licensing Agreement With Dynamiclear For Dynamiclear Rapid 62
QrxPharma Enters Into Licensing Agreement With Paladin Labs For Moxduo 63
Nuvo Research Enters Into Licensing Agreement With Paladin Labs For Synera 65
Par Pharma Enters Into Licensing Agreement With Handa Pharma For ANDA 66
Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 67
Paladin Labs Enters into Licensing Agreement With Immuron For Travelan 69
Somaxon Pharma Enters Into Licensing Agreement With Paladin Labs For Silenor 70
Paladin Labs Enters Into Licensing Agreement With Elan For Hydrocodone 71
Paladin Labs Enters Into Licensing And Distribution Agreement With Takeda For Fomepizole 72
MediGene Enters Into Licensing Agreement With Triton Pharma For Veregen 73
Auxilium Pharma Enters Into Licensing Agreement With Asahi Kasei For XIAFLEX 74
Endo International Raises USD2.3 Billion in Public Offering of Shares 76
Paladin Labs Completes Private Placement For US$40 Million 78
Endo International Prices Private Placement of 5.875% Notes Due 2024 for USD300 Million 80
Endo Prices Private Placement of Notes Due 2023 for USD1.6 Billion 81
Endo International Prices Private Placement of 6% Notes Due 2023 for USD1.64 Billion 82
Endo International Prices Private Placement of 6% Notes Due 2025 for USD1.2 Billion 83
Endo International Completes Private Placement of 5.375% Notes Due 2023 for USD750 Million 84
Endo Health Solutions Completes Private Placement Of Notes Due 2022 For US$700 Million 85
Auxilium Pharma Completes Public Offering Of Notes Due 2018 For US$350 Million 86
Par Pharma Completes Private Placement Of Notes Due 2020 For US$490 Million 87
Endo Pharma Completes Private Placement Of Senior Unsecured Notes Due 2019 For US$500 Million 88
Endo Pharma Completes Private Placement Of Senior Unsecured Notes Due 2022 For US$400 Million 89
Rising Pharma to Acquire Three ANDAs from Endo International 90
Braeburn Pharma Acquires Risperidone Implant from Endo Pharma 91
Nuvo Research Reacquires Pennsaid Rights from Paladin Labs 92
Rising Pharma Acquires Doxercalciferol, Paricalcitol and Dutasteride from Par Pharma 93
Trendlines Acquires Intellectual Property from Endo 94
AsanaBioSciences Completes Acquisition of Drug Discovery Platform from Endo Pharma 95
Acino Pharma Acquires Litha Healthcare from Endo International 96
Endo International Acquires Par Pharma from TPG Capital for USD8.05 Billion 98
Par Pharma Acquires Innoteq for USD27 Million 100
Endo International Acquires Auxilium Pharma for USD2.6 Billion 101
Par Pharma Reportedly Acquires Ethics Bio Lab 103
Endo International Completes Acquisition of Dava Pharma for USD600 Million 104
Endo International Completes Acquisition of Grupo Farmaceutico Somar 105
Endo Health Solutions Completes Acquisition Of Paladin Labs For US$1.6 Billion 106
Par Pharma Acquires JHP Group for USD488 Million 109
Endo Health Solutions Completes Acquisition Of Boca Pharmacal For US$225 Million 110
Paladin Labs Acquires Triton Pharma 112
Paladin Labs Completes Acquisition Of Allon Therapeutics 113
Auxilium Pharma Acquires Actient From GTRC 114
Paladin Labs Completes Acquisition Of Majority Stake In Ativa Pharma 116
Paladin Labs Completes Acquisition Of Remaining 55.01% Stake In Pharmaplan, Generic Pharma Company 117
Litha Healthcare Group Completes Acquisition Of Pharmaplan From Paladin Labs For US$60.7 Million 118
Par Pharma Completes Acquisition Of Edict Pharma, Generic Pharma Company, For US$24.9 Million 120
Par Pharma Acquires Anchen Pharma For US$410 Million 121
Paladin Labs Completes Acquisition Of Labopharm 123
Endo Pharma Acquires American Medical Systems 125
Endo Pharma To Acquire A Pharma Company 127
Endo International Plc, Key Competitors 128
Endo International Plc, Key Employees 129
Endo International Plc, Other Locations 131
Endo International Plc, Subsidiaries 131

List of Figures
Endo International Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 9
Endo International Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 10
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 11
Endo International Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 12
Endo International Plc, Medical Devices Deals, 2011 to YTD 2017 14

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Endo International Plc (ENDP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027